Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27604438 | 0.84 | CYP1A2 (0.33) | LTA4HNOS1NOS3NOS2CYP1A2 | |
| SCHEMBL30919265 | 0.84 | DPP4 (0.32) | LTA4H | |
| SCHEMBL30919281 | 0.84 | LTA4H (0.36) | LTA4H | |
| SCHEMBL28748529 | 0.83 | LTA4H (0.36) | LTA4HFAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26940364 | 0.83 | LTA4H (0.36) | LTA4HFAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18476646 | 0.81 | FAAH (0.38) | FAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18452613 | 0.81 | FAAH (0.38) | FAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18452721 | 0.80 | FAAH (0.34) | FAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26262639 | 0.80 | FAAH (0.34) | FAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29341620 | 0.80 | LTA4H (0.40) | LTA4HNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | LTA4H 1011/4885FAAH 1065/4885NOS1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.